Recent Updates
Recently added Catalysts

Pharming Group N.V.

PHARFDA catalysts, PDUFA dates & pipeline intelligence
$11.54
▼ -0.63 · -5.18%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full PHAR financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $9.1152W HIGH $21.34
Volume
10.51 K
Value Traded
123.40 K
Short % Float
-
Days to Cover
1.4
-8.41%Week
+19.59%1 Month
-2.62%3 Month
-8.41%6 Month
+43.68%5 Year
-21.35%All Time

Cash Data

Unlock PHAR cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
816.78 M
EPS (TTM)
0.18
P/E Ratio
64.87
Ent. Value
861.23 M
Total Shares
70.78 M
Float Shares
-
Insiders
-
Institutions
0.11%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 topline data readout
leniolisib
common variable immunodeficiency (CVID)
Phase 2Small MoleculesImmunology
Unlock every PHAR catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

PHAR Catalyst Timeline

Dated clinical, regulatory and corporate events for Pharming Group N.V.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Pharming Group N.V.

396Total events
21Upcoming
97Tier-1 (high impact)
2004 to 2028Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
LeniolisibApproved
T2Restructuring Layoffs
Subscribe to view catalyst details

Event history 50

▲MHRA MilestoneLeniolisibApprovedEx-US Regulatory
MHRA approves extension of Joenja marketing authorization to children aged 4-11 weighing ≥27 kg with APDS
activated PI3K delta syndrome (APDS)source ↗
▲Quarterly UpdateCorporate
Pharming reports Q3 2026 financial results with 21% revenue growth
▲Runway Guidance UpdateCorporate
2026 total revenue guidance tightened to US$380-390 million
▲Quarterly UpdateCorporate
Pharming announces preliminary Q3 2026 revenues of ~US$117.6M, up 21% YoY
▲Late-BreakerLeniolisibApprovedPresentation
Late-breaking abstract accepted for leniolisib Phase II PID data at ESID 2026
genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulationsource ↗
▲Poster PresentationLeniolisibApprovedPresentation
Late-breaking poster presentation of leniolisib Phase II PID data at ESID 2026
genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulationsource ↗
▲Topline ReadoutLeniolisibApprovedClinical Data
Positive Phase II topline data for leniolisib in genetically identifiable PIDs with immune dysregulation presented at ESID
genetically identifiable primary immunodeficiencies with immune dysregulationsource ↗
▲OLE InitiatedLeniolisibApprovedTrial
All 12 completers enrolled in three-year extension study of leniolisib
genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulationsource ↗
▲Safety Data UpdateLeniolisibApprovedClinical Data
Leniolisib well-tolerated with no new safety signals in Phase II PID trial
genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulationsource ↗
●Management ChangeCorporate
Fabrice Chouraqui stepped down as CEO; Leverne Marsh and Kenneth Lynard appointed Interim Co-CEOs
Unlock the full PHAR catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How PHAR actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-14leniolisib Phase 2 topline data readout Phase 2
Unlock 5 more PHAR historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 42%
Micro Cap
(rank 304 of 723)
Percentile Rank
Commercial products (revenue basis: latest annual revenue in its 20-F, to Dec 2025; product lines from the latest annual filing)
ProductRevenuePrior periodChange
RUCONEST
JOENJA
Showing 9 of 12 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Leniolisib Small MoleculesMarketedNCT05438407APDSApproved ACTIVE NOT_RECRUITING 31Dec 30, 2026
Leniolisib Small MoleculesNCT06990529PIDs Linked to PI3KPhase 2 ACTIVE NOT_RECRUITING 12Aug 12, 2029
Napazimone Small MoleculesNCT05650229Primary Mitochondrial DiseasePhase 2 RECRUITING 180Nov 1, 2027
Napazimone Small MoleculesNCT03888716Mitochondrial DiseasePhase 2 COMPLETED 226Mar 16, 2021
Leniolisib Small MoleculesNot countedNCT06549114Primary Immunodeficiency Disorders (PIDs)Phase 2 COMPLETED 13Jun 23, 2026
Leniolisib Small MoleculesNot countedNCT06897358Common Variable Immunodeficiency (CVID)Phase 2 COMPLETED 27Aug 12, 2026
Recombinant human C1 inhibitor BiologicsNot countedNCT02247739Hereditary AngioedemaPhase 3 COMPLETED 184Sep 1, 2016
Recombinant human C1 inhibitor Small MoleculesNot countedNCT00851409Genetic DisordersPhase 2 COMPLETED 25Apr 1, 2010
Ruconest Small MoleculesNot countedNCT04530136Confirmed Coronavirus DiseasePhase 2 COMPLETED 38Dec 1, 2021
Unlock the PHAR pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every PHAR program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
leniolisib
PriorityOrphan
genetic primary immunodeficiencies (PIDs) with immune dysregulationPhase 22026-10-14spleen volume reduction: 26.4% (n=11); lymph node reduction: 33.7% (n=4); pulmonary function improvement: 8.0% (n=7)Read MorePharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026Read More
Scroll for more · summaries link to the source press release
Unlock every PHAR trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock PHAR insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full PHAR insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in PHAR for Q3 2026.
Unlock every fund holding PHAR
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in PHAR
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see PHAR ownership
Insider and institutional ownership, quarter by quarter.

PHAR Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
25.8K
Shares Sold Short
+92.0% vs prior count
1.4 Low
Days to Cover
trading days of normal volume to buy every short share back
18.2K
Avg Daily Volume
the average used for days to cover
Unlock PHAR short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock PHAR option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live PHAR option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock PHAR options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How PHAR ranks across every disease it competes in

Competitive Position is a premium feature
See how PHAR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

PHAR News

PHAR
Nov 11, 2026
PHARConferences/Events

Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London

Pharming announced its participation in the 2026 Jefferies Global Healthcare Conference in London, scheduled for November 16-19, 2026. Key executives, including Interim Co-CEOs and the VP of Investor Relations, will host a fireside chat on November 18. A live webcast will be available for those unable to attend in person.

Read more →
PHAR
Nov 6, 2026
PHARFDA Updates

MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

The U.K. MHRA has approved Pharming's Joenja (leniolisib) for children aged 4 to 11 with activated PI3K delta syndrome (APDS). This marks the first treatment specifically for this age group in the U.K. Joenja is expected to be available by February 2027, expanding access for younger patients suffering from this rare immunodeficiency.

Read more →
PHAR
Oct 27, 2026
PHARGeneral

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Pharming Group reported a 21% increase in total revenues for Q3 2026, reaching $117.6 million, driven by strong demand for RUCONEST and Joenja. Operating profit rose 89% to $29.9 million, and the company tightened its revenue guidance for the year. Positive Phase II data for leniolisib in genetic PIDs was also announced, with further data expected in November.

Read more →
PHAR
Oct 22, 2026
PHARGeneral
▲ +10.6%on this news· ran to +23% by day 3shared move

Pharming Group announces third quarter 2026 revenues above market expectations

Pharming Group reported third quarter 2026 revenues of approximately US$117.6 million, a 21% increase from the same period in 2025. The company tightened its full-year revenue guidance to between US$380 million and US$390 million. Key revenue drivers included strong performances from RUCONEST and Joenja, with significant growth in international demand.

Read more →
PHAR
Oct 14, 2026
PHARPhases

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Pharming presented positive topline data from its Phase II trial of leniolisib for genetic primary immunodeficiencies (PIDs) with immune dysregulation. The trial demonstrated that leniolisib was well-tolerated and resulted in significant improvements in spleen volume, lymph node size, and pulmonary function. All participants who completed the trial chose to continue in a long-term extension study, indicating strong interest in the treatment's potential.

Read more →
PHAR
Sep 29, 2026
PHARGeneral

Pharming announces CEO transition

Pharming has announced a leadership transition as CEO Fabrice Chouraqui steps down. The Board of Directors appointed Leverne Marsh and Kenneth Lynard as Interim Co-CEOs to ensure continuity. The decision follows a mutual agreement on differing views regarding the company's strategic direction. Pharming's commitment to its patients and strategic priorities remains intact.

Read more →
PHAR
Sep 25, 2026
PHARFDA Updates

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Pharming announced that the FDA has accepted its supplemental New Drug Application for lower doses of Joenja, aimed at treating children aged 4 years and older with activated phosphoinositide 3-kinase delta syndrome (APDS). The application has been granted Priority Review, with a target action date set for January 30, 2027. This follows the recent approval of Joenja for older children weighing at least 27 kg, expanding access to younger patients.

Read more →
PHAR
Sep 22, 2026
PHARPhases

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Pharming announced positive topline data from its Phase II trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation. The results, accepted as a late-breaking abstract for ESID 2026, highlighted significant clinical improvements, including a mean 26.4% reduction in spleen volume. The drug was well-tolerated, with no new safety signals reported. Pharming plans to present additional data at the conference and expects to report results for leniolisib in common variable immunodeficiency (CVID) later this year.

Read more →
PHAR
Sep 11, 2026
PHARFDA Updates

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Pharming's Joenja (leniolisib) has received FDA approval for use in children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS). This marks the first FDA-approved treatment for this age group in the U.S. The new dosing options will be available in October, providing a critical intervention for managing APDS symptoms and improving children's health outcomes.

Read more →
PHAR
Sep 9, 2026
PHARConferences/Events

Pharming Group to participate in September investor conferences

Pharming Group N.V. announced its participation in two investor conferences in September 2026. CEO Fabrice Chouraqui will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, followed by participation in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The company encourages scheduling one-on-one meetings with its management team.

Read more →
PHAR
Aug 13, 2026
PHARFDA Updates

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

Pharming Group has launched Joenja (leniolisib) in Japan for patients aged 4 and older with activated PI3K delta syndrome (APDS). This marks the first commercial availability of Joenja for children aged 4 to 11 globally. The launch follows its approval by Japan's Ministry of Health and highlights Pharming's commitment to rare disease treatment.

Read more →
PHAR
Aug 4, 2026
PHARConferences/Events

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

Pharming Group N.V. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP of Investor Relations, will lead a Fireside Chat Q&A session on August 12. The company invites interested parties to schedule meetings with its management team during the conference.

Read more →
PHAR
Jul 30, 2026
PHARGeneral
▼ -10.5%on this newsshared move

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

Pharming Group N.V. reported a 3% decrease in total revenues for Q2 2026, totaling $90.2 million. While RUCONEST revenue fell by 10%, Joenja saw a significant 40% increase. The company revised its revenue guidance downward but remains optimistic about the growth potential of Joenja and upcoming clinical data readouts. Pharming is also focusing on operational efficiency and expanding its rare disease portfolio.

Read more →
PHAR
Jul 16, 2026
PHARConferences/Events

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

Pharming Group N.V. will report its preliminary financial results for the second quarter and first half of 2026 on July 30, 2026. The company will also provide a business update during a conference call and webcast scheduled for the same day. Interested participants must register in advance to access the call.

Read more →
PHAR
Jun 4, 2026
PHARFDA Updates

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming Group announced the FDA's acceptance of its resubmitted supplemental New Drug Application for Joenja (leniolisib) to treat children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). If approved, Joenja will be the first treatment for this rare immunodeficiency in the U.S. The resubmission includes additional data requested by the FDA and has a target action date of October 24, 2026.

Read more →
PHAR
Jun 2, 2026
PHARConferences/Events
▼ -6.3%on this newsshared move

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

Pharming Group announced its participation in the 2026 Jefferies Global Healthcare Conference in New York, scheduled for June 3-4, 2026. CEO Fabrice Chouraqui will take part in a Fireside Chat Q&A session on June 4 at 11:05am EDT. The event will be accessible via a live webcast and replay on Pharming's website.

Read more →
PHAR
May 28, 2026
PHARGeneral

Pharming Group announces results of 2026 Annual General Meeting of Shareholders

Pharming Group held its Annual General Meeting of Shareholders on May 28, 2026, where all proposed agenda items were approved. Key decisions included the appointment of KPMG as the independent auditor for 2026-2028 and amendments to the remuneration policy for Non-Executive Directors. Shareholders also renewed authorizations for share issuance and repurchase.

Read more →
PHAR
May 22, 2026
PHARFDA Updates

European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

The European Commission has granted marketing authorization for Joenja® (leniolisib), marking it as the first approved treatment for activated PI3K delta syndrome (APDS) in the EU. The drug is expected to launch in Germany in Q3 2026. This approval follows previous approvals in several countries, reinforcing Pharming's commitment to addressing rare diseases.

Read more →
PHAR
May 7, 2026
PHARConferences/Events
▼ -26.8%on this news

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Pharming Group N.V. announced its participation in the 2026 Annual Meeting of the Clinical Immunology Society, where it will present interim outcomes from a long-term study of leniolisib in pediatric patients with activated PI3Kδ syndrome (APDS). The presentations will also cover clinical data from leniolisib's use in treating immune dysregulation in patients with Common Variable Immunodeficiency (CVID) and related disorders. Two phase II trials are currently evaluating leniolisib's safety and tolerability in these patient populations.

Read more →
PHAR
May 7, 2026
PHARGeneral
▼ -26.8%on this newsshared move

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

Pharming Group reported its Q1 2026 financial results, revealing total revenues of $72.4 million, an 8% decrease from the previous year. Notably, Joenja® saw a 34% revenue increase, driven by strong uptake in the U.S. and international markets. The company reaffirmed its revenue guidance for 2026 and made significant regulatory progress, including approvals in Japan and a positive opinion from the CHMP in Europe.

Read more →

About Pharming Group N.V.

409 employees pharming.com
BIOPHARMAWATCH ELITE
Trade the next PHAR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime